HCV-话题@MedSci

#HCV#

247篇内容 | 3831人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=J Hepatol：直接抗病毒药物治疗导致HCV清除后，可改善患者颈动脉粥样硬化, objectType=article, longId=131891, objectId=505213189132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=505213189132, replyNumber=0, likeNumber=64, createdTime=2018-03-10, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=505213189132, moduleTitle=J Hepatol：直接抗病毒药物治疗导致HCV清除后，可改善患者颈动脉粥样硬化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=505213189132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257722, encodeId=121b125e72266, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=J Gastroenterol：DAA治疗导致HCV清除后，患者肝纤维化和血清APF水平得到改善, objectType=article, longId=131890, objectId=7ed913189055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ed913189055, replyNumber=0, likeNumber=74, createdTime=2018-03-10, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ed913189055, moduleTitle=J Gastroenterol：DAA治疗导致HCV清除后，患者肝纤维化和血清APF水平得到改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ed913189055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257721, encodeId=85ed125e72110, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Dig Liver Dis：真实世界中，OBT/PTV-r+RBV治疗HCV基因4型（进展期肝纤维化）患者，疗效良好，可获得较高SVR, objectType=article, longId=131797, objectId=3b1b131e97fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b1b131e97fa, replyNumber=0, likeNumber=72, createdTime=2018-03-09, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b1b131e97fa, moduleTitle=Dig Liver Dis：真实世界中，OBT/PTV-r+RBV治疗HCV基因4型（进展期肝纤维化）患者，疗效良好，可获得较高SVR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b1b131e97fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257720, encodeId=1abd125e7208a, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Circ J：HCV抗病毒治疗减少了心力衰竭等心血管事件的发生, objectType=article, longId=131796, objectId=f6ac131e9671, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6ac131e9671, replyNumber=0, likeNumber=136, createdTime=2018-03-09, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6ac131e9671, moduleTitle=Circ J：HCV抗病毒治疗减少了心力衰竭等心血管事件的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6ac131e9671)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257719, encodeId=be8b125e719a7, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=J Viral Hepat：在日本，采用口服DAA药物治疗HCV基因1b型患者，显著增加了直接和间接经济效益, objectType=article, longId=131014, objectId=e69813101429, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69813101429, replyNumber=0, likeNumber=54, createdTime=2018-03-02, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69813101429, moduleTitle=J Viral Hepat：在日本，采用口服DAA药物治疗HCV基因1b型患者，显著增加了直接和间接经济效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e69813101429)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257718, encodeId=5d45125e718d5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Gut Liver：Daclatasvir联合Asunaprevir治疗HCV基因1b型患者的疗效和安全性, objectType=article, longId=129711, objectId=5c2e129e11c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c2e129e11c9, replyNumber=0, likeNumber=84, createdTime=2018-02-13, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c2e129e11c9, moduleTitle=Gut Liver：Daclatasvir联合Asunaprevir治疗HCV基因1b型患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c2e129e11c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257717, encodeId=4cca125e7173a, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Gastroenterology：在HBV-HCV共感染细胞，HBV并没有阻止IFN对HCV复制的抑制作用, objectType=article, longId=129622, objectId=32f312962272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32f312962272, replyNumber=0, likeNumber=52, createdTime=2018-02-12, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32f312962272, moduleTitle=Gastroenterology：在HBV-HCV共感染细胞，HBV并没有阻止IFN对HCV复制的抑制作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32f312962272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257716, encodeId=f206125e716ce, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Liver Int：Sirt1通过PPARgamma2的表达来调控HCV核心蛋白1b诱导的肝脂肪变性, objectType=article, longId=129421, objectId=b16b129421ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b16b129421ee, replyNumber=0, likeNumber=61, createdTime=2018-02-10, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b16b129421ee, moduleTitle=Liver Int：Sirt1通过PPARgamma2的表达来调控HCV核心蛋白1b诱导的肝脂肪变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b16b129421ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257715, encodeId=6a86125e715f6, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Hepatol Res：Sofosbuvir联合ribavirin对肾功能不全的HCV基因2型日本患者的治疗是有效和安全的, objectType=article, longId=129140, objectId=4aca1291405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aca1291405d, replyNumber=0, likeNumber=58, createdTime=2018-02-08, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aca1291405d, moduleTitle=Hepatol Res：Sofosbuvir联合ribavirin对肾功能不全的HCV基因2型日本患者的治疗是有效和安全的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aca1291405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257714, encodeId=3353125e71467, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=J Med Virol：治疗前患者状况、AFP水平、RBV/体重(BW)比可作为sofosbuvir联合Ribavirin治疗HCV基因2型患者效果的独立预测因, objectType=article, longId=129137, objectId=3da312913ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3da312913ee7, replyNumber=0, likeNumber=64, createdTime=2018-02-08, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3da312913ee7, moduleTitle=J Med Virol：治疗前患者状况、AFP水平、RBV/体重(BW)比可作为sofosbuvir联合Ribavirin治疗HCV基因2型患者效果的独立预测因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3da312913ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257713, encodeId=6e64125e7135e, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=N Engl J Med：Glecaprevir-Pibrentasvir治疗HCV基因1或3型患者，可达到很好的治疗效果, objectType=article, longId=129002, objectId=6d3e1290027e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d3e1290027e, replyNumber=0, likeNumber=61, createdTime=2018-02-07, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d3e1290027e, moduleTitle=N Engl J Med：Glecaprevir-Pibrentasvir治疗HCV基因1或3型患者，可达到很好的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d3e1290027e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257712, encodeId=b9b4125e71217, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Liver Int：接受DAA与利巴韦林联合治疗的HCV患者，利巴韦林剂量的调整并不影响治疗效果, objectType=article, longId=128706, objectId=c333128e0626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c333128e0626, replyNumber=0, likeNumber=69, createdTime=2018-02-04, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c333128e0626, moduleTitle=Liver Int：接受DAA与利巴韦林联合治疗的HCV患者，利巴韦林剂量的调整并不影响治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c333128e0626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257711, encodeId=c9e8125e711e0, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Liver Int：HCV-DAA治疗对细胞外囊泡miRNAs含量及免疫调节性能的影响, objectType=article, longId=128006, objectId=2787128006d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2787128006d1, replyNumber=0, likeNumber=71, createdTime=2018-01-29, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2787128006d1, moduleTitle=Liver Int：HCV-DAA治疗对细胞外囊泡miRNAs含量及免疫调节性能的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2787128006d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257710, encodeId=4394125e71030, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=J Hepatol：在资源有限的情况下，直接抗病毒药物治疗HCV患者的经验及教训, objectType=article, longId=128000, objectId=4355128000b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4355128000b8, replyNumber=0, likeNumber=58, createdTime=2018-01-29, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4355128000b8, moduleTitle=J Hepatol：在资源有限的情况下，直接抗病毒药物治疗HCV患者的经验及教训, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4355128000b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257709, encodeId=e7a7125e70917, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=NEJM：Glecaprevir-Pibrentasvir治疗HCV1或3型感染, objectType=article, longId=127679, objectId=1b0712e679e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b0712e679e0, replyNumber=0, likeNumber=44, createdTime=2018-01-27, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b0712e679e0, moduleTitle=NEJM：Glecaprevir-Pibrentasvir治疗HCV1或3型感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b0712e679e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257708, encodeId=07cf125e70876, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=J Hepatol：无干扰素治疗清除HCV后，并发症对患者预后的影响, objectType=article, longId=127633, objectId=f0b512e63379, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b512e63379, replyNumber=0, likeNumber=54, createdTime=2018-01-26, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b512e63379, moduleTitle=J Hepatol：无干扰素治疗清除HCV后，并发症对患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b512e63379)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257707, encodeId=a809125e70776, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Lancet Gastroen Hepatol：HCV抗病毒治疗过程中的HBV再激活风险, objectType=article, longId=127564, objectId=bc6c12e56400, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc6c12e56400, replyNumber=0, likeNumber=73, createdTime=2018-01-26, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc6c12e56400, moduleTitle=Lancet Gastroen Hepatol：HCV抗病毒治疗过程中的HBV再激活风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc6c12e56400)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257706, encodeId=ff42125e70689, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Liver Int：HCV肝硬化失代偿患者对医院造成了相当大的住院负担, objectType=article, longId=127319, objectId=fd6c12e31999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd6c12e31999, replyNumber=0, likeNumber=51, createdTime=2018-01-24, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd6c12e31999, moduleTitle=Liver Int：HCV肝硬化失代偿患者对医院造成了相当大的住院负担, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd6c12e31999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257705, encodeId=5a09125e70590, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=J Viral Hepat：波兰HCV患者经直接抗病毒药物治疗的疗效和安全性, objectType=article, longId=127298, objectId=ff0b12e2981c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0b12e2981c, replyNumber=0, likeNumber=50, createdTime=2018-01-24, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0b12e2981c, moduleTitle=J Viral Hepat：波兰HCV患者经直接抗病毒药物治疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0b12e2981c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257704, encodeId=7932125e704d0, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, objectTitle=Lancet Gastroen Hepatol：索非布韦联合维帕他韦对吸毒患者的HCV感染有效, objectType=article, longId=125922, objectId=d0621259220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0621259220a, replyNumber=0, likeNumber=72, createdTime=2018-01-10, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0621259220a, moduleTitle=Lancet Gastroen Hepatol：索非布韦联合维帕他韦对吸毒患者的HCV感染有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0621259220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCV

2020-05-29

ymljack (审核中...)

前往app查看评论内容

#HCV#

J Hepatol：直接抗病毒药物治疗导致HCV清除后，可改善患者颈动脉粥样硬化

2018-03-10

ymljack (审核中...)

前往app查看评论内容

#HCV#

J Gastroenterol：DAA治疗导致HCV清除后，患者肝纤维化和血清APF水平得到改善

2018-03-10

ymljack (审核中...)

前往app查看评论内容

#HCV#

Dig Liver Dis：真实世界中，OBT/PTV-r+RBV治疗HCV基因4型（进展期肝纤维化）患者，疗效良好，可获得较高SVR

2018-03-09

ymljack (审核中...)

前往app查看评论内容

#HCV#

Circ J：HCV抗病毒治疗减少了心力衰竭等心血管事件的发生

2018-03-09

ymljack (审核中...)

前往app查看评论内容

#HCV#

J Viral Hepat：在日本，采用口服DAA药物治疗HCV基因1b型患者，显著增加了直接和间接经济效益

2018-03-02

ymljack (审核中...)

前往app查看评论内容

#HCV#

Gut Liver：Daclatasvir联合Asunaprevir治疗HCV基因1b型患者的疗效和安全性

2018-02-13

ymljack (审核中...)

前往app查看评论内容

#HCV#

Gastroenterology：在HBV-HCV共感染细胞，HBV并没有阻止IFN对HCV复制的抑制作用

2018-02-12

ymljack (审核中...)

前往app查看评论内容

#HCV#

Liver Int：Sirt1通过PPARgamma2的表达来调控HCV核心蛋白1b诱导的肝脂肪变性

2018-02-10

ymljack (审核中...)

前往app查看评论内容

#HCV#

Hepatol Res：Sofosbuvir联合ribavirin对肾功能不全的HCV基因2型日本患者的治疗是有效和安全的

2018-02-08

ymljack (审核中...)

前往app查看评论内容

#HCV#

J Med Virol：治疗前患者状况、AFP水平、RBV/体重(BW)比可作为sofosbuvir联合Ribavirin治疗HCV基因2型患者效果的独立预测因

2018-02-08

ymljack (审核中...)

前往app查看评论内容

#HCV#

N Engl J Med：Glecaprevir-Pibrentasvir治疗HCV基因1或3型患者，可达到很好的治疗效果

2018-02-07

ymljack (审核中...)

前往app查看评论内容

#HCV#

Liver Int：接受DAA与利巴韦林联合治疗的HCV患者，利巴韦林剂量的调整并不影响治疗效果

2018-02-04

ymljack (审核中...)

前往app查看评论内容

#HCV#

Liver Int：HCV-DAA治疗对细胞外囊泡miRNAs含量及免疫调节性能的影响

2018-01-29

ymljack (审核中...)

前往app查看评论内容

#HCV#

J Hepatol：在资源有限的情况下，直接抗病毒药物治疗HCV患者的经验及教训

2018-01-29

ymljack (审核中...)

前往app查看评论内容

#HCV#

NEJM：Glecaprevir-Pibrentasvir治疗HCV1或3型感染

2018-01-27

ymljack (审核中...)

前往app查看评论内容

#HCV#

J Hepatol：无干扰素治疗清除HCV后，并发症对患者预后的影响

2018-01-26

ymljack (审核中...)

前往app查看评论内容

#HCV#

Lancet Gastroen Hepatol：HCV抗病毒治疗过程中的HBV再激活风险

2018-01-26

ymljack (审核中...)

前往app查看评论内容

#HCV#

Liver Int：HCV肝硬化失代偿患者对医院造成了相当大的住院负担

2018-01-24

ymljack (审核中...)

前往app查看评论内容

#HCV#

J Viral Hepat：波兰HCV患者经直接抗病毒药物治疗的疗效和安全性

2018-01-24

ymljack (审核中...)

前往app查看评论内容

#HCV#

Lancet Gastroen Hepatol：索非布韦联合维帕他韦对吸毒患者的HCV感染有效

2018-01-10

科室
- - 订阅+
  - 更多科室
工具
服务